Detalhe da pesquisa
1.
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
N Engl J Med;
386(22): 2084-2096, 2022 06 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35507508
2.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med;
21(3): e1004360, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38502656
3.
Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
J Infect Dis;
2023 Oct 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37795976
4.
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
J Infect Dis;
226(2): 246-257, 2022 08 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35758878
5.
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
PLoS Med;
17(2): e1003038, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32092060
6.
Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.
J Virol;
92(20)2018 10 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30089691
7.
Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates.
Nat Commun;
14(1): 1309, 2023 03 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36894558
8.
Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
Commun Med (Lond);
3(1): 75, 2023 May 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37237062
9.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.
medRxiv;
2023 Jan 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36523415
10.
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.
Lancet Respir Med;
11(11): 975-990, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37716365
11.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
EClinicalMedicine;
62: 102109, 2023 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37533419
12.
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
EClinicalMedicine;
64: 102168, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37936652
13.
Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates.
Nat Commun;
13(1): 1699, 2022 03 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35361754
14.
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study.
Front Immunol;
13: 939627, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35935978
15.
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Lancet Infect Dis;
22(5): 636-648, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35090638
16.
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
Clin Infect Dis;
52(4): 522-31, 2011 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21208909
17.
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Lancet Infect Dis;
21(9): 1257-1270, 2021 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33887209
18.
Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates.
bioRxiv;
2021 Mar 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33688652
19.
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
Sci Transl Med;
13(607)2021 08 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34315825
20.
Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination.
Vaccine;
38(7): 1678-1689, 2020 02 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31932137